Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples